Drug Shortage Report for TRELEGY ELLIPTA
Report ID | 178694 |
Drug Identification Number | 02474522 |
Brand name | TRELEGY ELLIPTA |
Common or Proper name | fluticasone furoate, umeclidinium and vilanterol dry powder for oral inhalation |
Company Name | GLAXOSMITHKLINE INC |
Market Status | MARKETED |
Active Ingredient(s) | VILANTEROL UMECLIDINIUM FLUTICASONE FUROATE |
Strength(s) | 25MCG 62.5MCG 100MCG |
Dosage form(s) | POWDER |
Route of administration | INHALATION INHALATION |
Packaging size | 1x30 |
ATC code | R03AL |
ATC description | |
Reason for shortage | Demand increase for the drug. |
Anticipated start date | |
Actual start date | 2022-12-12 |
Estimated end date | 2023-01-06 |
Actual end date | 2023-01-03 |
Shortage status | Resolved |
Updated date | 2023-01-04 |
Company comments | Managing supply due to high demand. |
Health Canada comments | |
Tier 3 Status | No |
Company contact information | 1-800-387-7374 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v4 | 2023-01-04 | French | Compare |
v3 | 2023-01-04 | English | Compare |
v2 | 2022-12-16 | French | Compare |
v1 | 2022-12-16 | English | Compare |
Showing 1 to 4 of 4